Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Marion Webb

Managing Editor

San Diego, CA

Marion Webb has been writing about health care issues for nearly two decades as a full-time reporter and freelancer. As the senior business reporter for the San Diego Business Journal, Marion covered new medical innovations at San Diego’s top-ranking research institutions and the medical device and life sciences industry for nearly eight years. She’s also been a regular contributor to the Los Angeles County Medical Association’s Physician Magazine and Physicians News Network focusing on new technologies, practice management, reimbursement and other trendy issues relevant to physician practices and their ability to succeed. She remains fascinated by the ever-growing numbers of innovative products coming out of the medtech sector, from potentially life-saving devices to help treat patients who otherwise wouldn’t have access to medical care to breakthrough technologies that benefit mankind. Marion earned her BA in communications from UC San Diego and continues to enjoy an active lifestyle in San Diego.

Advertisement
Set Alert for Articles By Marion Webb

Latest From Marion Webb

Device Week, Aug. 14, 2018 – The Promising Landscape Of Liquid Biopsy

On this week's podcast, Medtech Insight's Reed Miller talks to Marion Webb about her latest two-part Market Intelligence series on the liquid biopsy market.

Device Week Cancer

Market Intel: Liquid Biopsy II – Emerging Companies Look For Liquid Gold

The potential to use a simple blood test to guide physicians in monitoring cancer therapies, detect early cancers, serve as a companion diagnostic to guide targeted therapeutics and predict the likely course or outcomes of disease in patients has spurred a lot of interest and innovation. Here's a look at emerging companies hoping to make an impact, including insights from interviews conducted with C-Level visitors at the recent Liquid Biopsy Conference in San Francisco. This is the second of a two-part series focusing on the global liquid biopsy market.

Cancer Personalized Medicine

Profusa Raised $45M To Market PAD-Monitoring Implant In Europe

Digital Health company Profusa raised more than $45m in a series C financing round. The company plans to use the proceeds to bring its tiny CE-marked injectable biosensors, used to monitor tissue oxygenation in patients with peripheral artery disease, to key opinion leaders and clinicians in Europe.

Wound Management Digital Health

Exoskeleton Company Ekso Bionics Names John (Jack) Glenn as CFO

Richmond, Calif.-based exoskeleton company Ekso Bionics named Jack Glenn as chief financial officer.

Appointments Commercial

Market Intel: Liquid Biopsy I – Analyzing Market Landmarks And Landmines

The worldwide liquid biopsy market is expected to reach $2.0bn by 2022, according to a new report by Meddevicetracker, "Oncology: Liquid Biopsy Products." The growth is driven by the rising global incidence of cancers, which, in turn, fuels innovation among companies to develop noninvasive diagnostic assays that obviate the need for tissue biopsy. This is the first in a two-part series providing an overview of the liquid biopsy market, as well as the technologies developed by the larger players in this space, and examining the biggest barriers and growth drivers. In the second part, we'll take a closer look at emerging companies in the sector and offer key insights from C-level attendees at the recent Liquid Biopsy Conference in San Francisco.

Cancer In Vitro Diagnostics

Laboratory For Advanced Medicine (LAM) Appoints Chief Regulatory Officer

Liquid biopsy developer Laboratory for Advanced Medicine (LAM) named Jinjie Hu as chief regulatory officer.

Appointments Commercial
See All
Advertisement
UsernamePublicRestriction

Register